SEPTIN9 methylation in ctDNA predicts MRD in colorectal cancer patients post-surgery
The study evaluates SEPTIN9 methylation status in ctDNA as a biomarker for minimal residual disease in colorectal cancer.
Asset / Drug
Drug and asset intelligence for SEPTIN9 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.